-
1 month ago | 
healio.com | Andrew Rhoades |Harold Bays
Key takeaways:Some obesity drugs in development have different mechanisms of action and may cost less than currently available drugs. However, educating clinicians about all these drugs may present a challenge. Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity Medicine 2025.
-
2 months ago | 
healio.com | Andrew Rhoades |Harold Bays
NATIONAL HARBOR, Md. —In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline. There is an “unbelievable number of anti-obesity drugs in development,” including GLP-1 receptor agonists with other incretins and appetite suppressants, Bays, chief science officer and president-elect of the Obesity Medicine Association, told Healio.
-
Feb 28, 2025 | 
uscjournal.com | Harold Bays |Naveed Sattar |Gurleen Kaur |Saman Nematollahi
Average (ratings) Abstract With the dawn of advanced technological and digital resources, medical education has changed. Learners are now able to learn, share, and communicate medical knowledge through online discussion forums, blogs, videos, podcasts, infographics, virtual communities, social media platforms, and collaborative author groups. Navigating these digital education modalities can be challenging, with each platform presenting unique challenges and opportunities.
-
Nov 27, 2024 | 
radcliffecvrm.com | Harold Bays |Lydia Alexander |Harriette Van Spall
Video Published: Views: 36 Likes: 0 Average (ratings) AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events. Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).
-
Nov 18, 2024 | 
radcliffecvrm.com | Harriette Van Spall |Harold Bays |Mikhail Kosiborod
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile. Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD). The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes.
-
Nov 8, 2024 | 
uscjournal.com | Harold Bays |Kadijah Porter |Brototo Deb |Andriy Katyukha
Vast disparities in cardiovascular morbidity and mortality exist, which partly stem from the underrepresentation of minoritized individuals in clinical research and clinical trials. These disparities encompass sociodemographic factors, such as race, ethnicity, and income status. Another significant source of disparity is biological sex, which is often misconstrued as gender in cardiovascular research.
-
May 31, 2024 | 
healio.com | Erik Swain |Richard Smith |Harold Bays
Read more You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Obesity increases heart disease risk, in part due to adverse effects on lipids.
-
May 30, 2024 | 
radcliffecardiology.com | Harriette Van Spall |Harold Bays |Sven Francque |Barbara McGowan
ECO 2024 — Dr Donna H Ryan (Pennington Biomedical Research Center, US) joins us to discuss the first sub-analysis of the landmark SELECT trial (NCT03574597, Novo Nordisk). In this study, investigators looked at long-term weight loss with semaglutide 2.4 mg compared to a placebo among 17,604 participants. In SELECT, at 208 weeks, semaglutide produced clinically significant weight loss compared to placebo. Weight loss was sustained over 4 years.
-
May 29, 2024 | 
radcliffecardiology.com | Harold Bays |Sven Francque |Donna Ryan |Naveed Sattar
Video Published: Views: 34 Likes: 0 Average (ratings) ECO 2024 — Prof Barbara McGowan (Guy's and St Thomas' Hospital & King's College, UK) joins us to discuss the findings from the STEP 10 trial (NCT05040971, Novo Nordisk). This Phase 3 randomised clinical trial investigated the efficacy and safety of subcutaneous semaglutide 2.4 mg (GLP-1 RA) in 181 participants with obesity (BMI greater than or equal to 30.0 kg/m^2) and prediabetes.
-
May 29, 2024 | 
radcliffecardiology.com | Harold Bays |Sven Francque |Barbara McGowan |Donna Ryan
Video Published: Views: 31 Likes: 0 Average (ratings) ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA. Questions1. What is the background of this combinatory approach? 2. What data did you present at ERA 24? 3. What are the challenges and opportunities in approaching combinatory treatment? 4.
